Xinhuanet Deqing, May 9 (Wu Qilong) On May 9, the "2025 Brand High-Quality Overseas Forum" hosted by Xinhuanet and Xinhua News Agency New Media Center was held in Deqing, Zhejiang. At the forum, Meng Weining, vice president and general manager of international business of Beijing Kexing Holdings (Group) Co., Ltd., said in a theme sharing speech that as the global epidemic risk infectious disease intensifies, vaccines, as an important guarantee for public health safety, are crucial to their accessibility and affordability.

Meng Weining, Vice President and General Manager of International Business, Beijing Kexing Holdings (Group) Co., Ltd.

According to Meng Weining, the current global vaccine supply is highly concentrated in four major multinational companies, accounting for more than 70% of the global market share, and most countries rely on external supply. Chinese vaccine companies have formed a complete industrial chain, able to produce 9 major categories and 33 vaccines, covering 60 sub-categories, with a huge production capacity and a ability to serve the world.

He said: "In the past, Chinese vaccine companies focused more on the domestic market. In recent years, with the growth of performance of companies such as Sinovac, Watson, and Zhongsheng overseas, more and more people in developing countries have begun to use Chinese vaccines, and international market opportunities have increased significantly."

As a pioneer in China's vaccine overseas, Sinovac actively promotes the implementation of localized production projects while supplying vaccines overseas. Meng Weining said that this move aims to continuously improve the accessibility and affordability of vaccines and benefit more countries.

Among the "Typical Case of Brands Going Over the Sea" announced at this forum, Sinovac Group was selected as the "Local Innovation Cases" by relying on its practice of actively promoting localized production in overseas markets. He also specifically mentioned that with the increase in industrial localization opportunities, vaccine-related supply chain links will be driven to go overseas in a coordinated manner, and open up a broader international space for Chinese vaccine companies.

"Although vaccines account for a limited proportion in the pharmaceutical industry, they have a huge role in public health and disease prevention and control. More and more countries have regarded vaccine production capacity as an important guarantee for national public health security." He said that Chinese vaccine companies are moving from "meeting domestic demand" to "serving global public health" with their technological accumulation and production capacity advantages, and playing an increasingly important role in the global vaccine supply chain.

Looking ahead, Meng Weining believes that with the deepening of cooperation between "Healthy China" and global public health, China's vaccines going overseas will rely on localized production and the coordination of the entire industrial chain to achieve the upgrade from product output to technology output and ecological co-construction, and contribute more Chinese strength to global disease prevention and control.

From May 9th to 11th, the 2025 World Brand Moganshan Conference was held in Deqing, Zhejiang. The World Brand Moganshan Conference was co-founded by Xinhua News Agency Brand Work Office, China National Brand Network, etc., and has been held for two consecutive sessions. As one of the important activities of the 2025 World Brand Moganshan Conference, the "2025 Brand High-Quality Overseas Overseas Forum" is themed "New Challenges, New Opportunities and New Paths", bringing together the wisdom of all parties to jointly explore diversified development paths for brands to go overseas.

[Editor in charge: Sun Hui]